Pharmaceutical - Stivarga

Filter

Current filters:

Stivarga

Popular Filters

Moderate growth forecast for colorectal cancer drug market

22-01-2015

The value of the colorectal cancer (CRC) therapeutics market will increase moderately, from $8.3 billion…

AvastinBayerBristol-Myers SquibbErbituxGlobalMarkets & MarketingMerck KGaAOncologyPharmaceuticalRocheStivarga

Bayer boasts strong R&D pipeline and growth prospects

03-12-2014

German pharma major Bayer gave a spirited presentation of its pipeline candidates in both pharma and…

AdempasBayerEyleaFinancialHematologyOncologyOphthalmicsPharmaceuticalResearchStivargaXareltoXofigo

Imatinib and sunitinib will continue to dominate patient share in GIST treatment

Imatinib and sunitinib will continue to dominate patient share in GIST treatment

11-08-2014

The treatment landscape of gastrointestinal stromal tumors (GIST) will not change dramatically through…

BayerGleevecGlivecMarkets & MarketingNovartisOncologyPfizerPharmaceuticalStivargaSutent

Bayer foresees 8% pa sales growth for pharma through 2016

Bayer foresees 8% pa sales growth for pharma through 2016

13-03-2014

Germany’s Bayer expects strong growth for its pharmaceutical business as a result of a number of new…

AdempasBayerEyleaFinancialPharmaceuticalStivargaXareltoXofigo

Hint of minor added benefit for Bayer’s Stivarga seen by IQWiG

Hint of minor added benefit for Bayer’s Stivarga seen by IQWiG

13-01-2014

There was a hint of positive news for German drug major Bayer, when the German Institute for Quality…

BayerGermanyNorthern EuropeOncologyPharmaceuticalPricingRegulationStivarga

Fast growth forecast for China’s colorectal cancer market

Fast growth forecast for China’s colorectal cancer market

13-12-2013

From 2012 to 2017, the colorectal cancer therapy market in China will grow at an annual rate of 9%, from…

AmgenAsia-PacificBayerIndiaMarkets & MarketingOncologyPharmaceuticalSanofiStivargaVectibixZaltrap

Bayer files for EU approval of regorafenib for GIST

05-09-2013

German pharma major Bayer (BAYN: DE) said this morning (September 5) that it has submitted an application…

BayerEuropeOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibRegulationStivarga

Bayer and Onyx' Stivarga cleared in Europe

30-08-2013

In a second piece of good news within a couple of days for German drug major Bayer (BAYN: DE), the European…

BayerEuropeOncologyOnyx PharmaceuticalsPharmaceuticalRegulationStivarga

Bayer gets Japanese OK for GI stromal tumors drug

20-08-2013

German drug major Bayer (BAYN: DE) has received approval from the Ministry of Health, Labor and Welfare…

Asia-PacificBayerBiotechnologyOncologyPharmaceuticalRegulationStivarga

US and European Rxing decisions on metastatic colorectal cancer

15-07-2013

The effect of a therapy on overall survival and progression-free survival are attributes that most influence…

AvastinBayerEli LillyEuropeMarkets & MarketingNorth AmericaOncologyPharmaceuticalramucirumabRegeneronRocheSanofiStivargaZaltrap

Bayer initiates Ph III Stivarga study in liver cancer; Sanofi enrolls sarilumab patients

15-05-2013

German drug major Bayer (BAYN: DE) says that patient enrollment is underway for RESORCE (Regorafenib…

Anti-Arthritics/RheumaticsBayerOncologyPharmaceuticalRegeneronResearchSanofisarilumabStivarga

FDA expands use of Bayer and Onyx' Stivarga for advanced GIST

26-02-2013

The US Food and Drug Administration yesterday expanded the approved use of German drug major Bayer's…

BayerNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalRegulationStivarga

Bayer's regorafenib overcomes resistance in patients with rare sarcoma

22-11-2012

A new targeted drug - German drug major Bayer's (BAYN: DE) regorafenib (trade name Stivarga) - demonstrated…

BayerBiotechnologyOncologyPharmaceuticalregorafenibResearchStivarga

Bayer initiates Ph III trail of Xarelto in cardiac event prevention; R&D day presentation

14-11-2012

German drug major Bayer (BAYN: DE) has initiated the Phase III COMPASS study of its oral anticoagulant…

AlpharadinBayerCardio-vascularOncologyOphthalmicsPharmaceuticalResearchStivargaXarelto

News briefs: Bayer's Stivarga and AstraZeneca's Faslodex

30-10-2012

German drug major Bayer (BAYN: DE) and US partner Onyx Pharmaceuticals (Nasdaq: ONXX) said yesterday…

AstraZenecaBayerFaslodexNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalRegulationResearchStivarga

Early FDA approval for Bayer's Stivarga in advanced colorectal cancer

28-09-2012

Bayer said Stivarga will be ready for distribution as soon as today (September 28 and set a wholesale…

BayerNorth AmericaOncologyPharmaceuticalregorafenibRegulationStivarga

COMPANY SPOTLIGHT

Menarini

Back to top